# Donanemab Breakthrough: Lower Amyloid, Better Outcomes! Newsy: Alzheimer’s News Weekly Published: 2025-10-20T13:30:00.171Z Source: https://newsyai.com/edition/498c4cf4-3edc-40da-bf41-93eadcc1ba01 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # The Alzheimer’s Treatment Briefing Coverage period: October 14–20, 2025 (U.S.) Below are this week’s most important, treatment‑relevant developments—ranked, plain‑English, and to the point. ## Top stories (ranked) 1) Donanemab “treat‑to‑target” signal: lower amyloid linked to better outcomes - What’s new - A new analysis of the large TRAILBLAZER‑ALZ 2 trial (published October 13) found that people whose brain amyloid was driven to very low levels after donanemab infusions tended to do better on thinking and daily‑function tests than those with higher residual amyloid. In short: deeper plaque clearance tracked with better clinical results. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2839837?utm_source=openai)) - Why this matters - This supports a practical goal for care teams: aim to get amyloid “as low as safely possible,” then consider pausing treatment. That could shape dosing schedules, MRI monitoring, and stop‑rules in clinics using donanemab. It also strengthens the case that clearing amyloid—when done safely—can translate into real‑world benefit. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2839837?utm_source=openai)) 2) Primary‑care blood test to quickly rule out Alzheimer’s‑type brain changes is now cleared - What’s new - The FDA cleared Roche/Eli Lilly’s Elecsys pTau181 blood test for adults 55+ with memory concerns in primary care. A negative result ruled out Alzheimer’s‑type changes with 97.9% accuracy in a 312‑person study, and the company says more than 4,500 analyzers are already in U.S. labs, enabling fast rollout. (Clearance announced October 13–14 coverage). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Why this matters - Faster answers, fewer invasive tests. Many people can be told—after a routine blood draw—that Alzheimer’s‑type changes are unlikely, avoiding spinal taps or PET scans. Those who screen positive can be prioritized for confirmatory testing and earlier treatment discussions. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) 3) Diabetes medicines linked to lower Alzheimer’s risk in real‑world data - What’s new - A new summary from Cleveland Clinic researchers (October 15) highlights observational evidence that starting GLP‑1 drugs (like semaglutide‑class medicines) or SGLT2 drugs is associated with a reduced risk of developing Alzheimer’s compared with another diabetes drug class (DPP‑4s). These are not definitive trials, but they add weight to ongoing studies of GLP‑1s in early Alzheimer’s. ([consultqd.clevelandclinic.org](https://consultqd.clevelandclinic.org/two-antidiabetic-drug-classes-may-curb-alzheimers-risk/?utm_source=openai)) - Why this matters - If randomized trials confirm even modest brain benefit, an easy‑to‑take medicine already used for diabetes and weight could become an add‑on (or alternative) to antibody infusions for some people—broadening options beyond infusions and frequent MRIs. ([consultqd.clevelandclinic.org](https://consultqd.clevelandclinic.org/two-antidiabetic-drug-classes-may-curb-alzheimers-risk/?utm_source=openai)) 4) Texas advances a ballot measure to create a $3B state dementia institute - What’s new - Texas voters will decide November 4 on creating the Dementia Prevention and Research Institute of Texas, with $3 billion proposed for research, prevention, workforce, and care. This would mirror the state’s cancer institute model that helped attract top researchers and trials. (Coverage October 16.) ([statesman.com](https://www.statesman.com/news/healthcare/article/university-texas-dementia-institute-vote-21098656.php?utm_source=openai)) - Why this matters - Big, stable funding can speed drug trials, build treatment centers, and expand access to cutting‑edge therapies—potentially improving how quickly Texans can get new Alzheimer’s treatments and related scans/tests. ([statesman.com](https://www.statesman.com/news/healthcare/article/university-texas-dementia-institute-vote-21098656.php?utm_source=openai)) 5) Medicare timing and logistics: updates that affect treatment access this fall - What’s new - Medicare open enrollment (Oct 15–Dec 7) is underway. CMS also issued an October 15 MLN update on claim holds for certain services amid federal payment legislation, and continues to outline how Part B covers anti‑amyloid antibodies (like lecanemab) when registry and diagnostic criteria are met. ([cms.gov](https://www.cms.gov/training-education/medicare-learning-network/newsletter/mln-connects-newsletter-october-15-2025?utm_source=openai)) - Why this matters - The best therapy still requires coverage. Plan choices, registries, and billing logistics directly affect out‑of‑pocket costs and how smoothly people start or continue treatments that slow decline. ([medicare.gov](https://www.medicare.gov/coverage/monoclonal-antibodies-for-the-treatment-of-early-alzheimers-disease?utm_source=openai)) ## What this means in plain language - Deeper amyloid clearing with donanemab is linked to better day‑to‑day outcomes. That gives clinics a clearer target: remove more plaque—safely—then reassess whether to pause therapy. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2839837?utm_source=openai)) - A simple blood draw in primary care can now help quickly sort who likely does—and does not—have Alzheimer’s‑type brain changes, speeding the pathway to the right next steps. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Diabetes/weight‑loss medicines continue to look promising in big “real‑world” datasets; we’re awaiting randomized trial results to know if they truly slow decline. ([consultqd.clevelandclinic.org](https://consultqd.clevelandclinic.org/two-antidiabetic-drug-classes-may-curb-alzheimers-risk/?utm_source=openai)) - State‑level funding (Texas) could accelerate trials and treatment access—watch this vote if you live in or get care in Texas. ([statesman.com](https://www.statesman.com/news/healthcare/article/university-texas-dementia-institute-vote-21098656.php?utm_source=openai)) - Medicare details still matter: confirm your plan and clinic meet current coverage rules for anti‑amyloid drugs, and expect some administrative friction during claim‑hold periods. ([cms.gov](https://www.cms.gov/training-education/medicare-learning-network/newsletter/mln-connects-newsletter-october-15-2025?utm_source=openai)) ## Quick guidance for patients and caregivers this week - Ask about blood testing in primary care - Would a pTau181 blood test help rule out Alzheimer’s‑type changes before more invasive tests? How would the result change your next step? ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - If considering antibody infusions (lecanemab or donanemab) - Discuss targets and monitoring: how low your team aims to drive amyloid, MRI safety checks, and when treatment might be paused. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2839837?utm_source=openai)) - During open enrollment (Oct 15–Dec 7) - Compare plans for coverage of infusions, MRIs, and required diagnostic tests. Confirm your clinician participates in the Medicare registry if you’re pursuing lecanemab. ([medicare.gov](https://www.medicare.gov/coverage/monoclonal-antibodies-for-the-treatment-of-early-alzheimers-disease?utm_source=openai)) ## Sources and further reading - JAMA Neurology (Oct 13, 2025): Post‑treatment amyloid levels vs outcomes after donanemab. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2839837?utm_source=openai)) - Reuters/Washington Post coverage of FDA‑cleared Elecsys pTau181 primary‑care blood test (Oct 13–14). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Cleveland Clinic (Oct 15): GLP‑1/SGLT2 drugs linked to lower Alzheimer’s risk in real‑world data. ([consultqd.clevelandclinic.org](https://consultqd.clevelandclinic.org/two-antidiabetic-drug-classes-may-curb-alzheimers-risk/?utm_source=openai)) - Austin American‑Statesman (Oct 16): Texas ballot measure for a $3B dementia institute. ([statesman.com](https://www.statesman.com/news/healthcare/article/university-texas-dementia-institute-vote-21098656.php?utm_source=openai)) - CMS MLN update (Oct 15) and Medicare coverage pages for anti‑amyloid antibodies. ([cms.gov](https://www.cms.gov/training-education/medicare-learning-network/newsletter/mln-connects-newsletter-october-15-2025?utm_source=openai)) If you’d like, I can watch for the first Phase 3 readouts of semaglutide in early Alzheimer’s and report the moment they drop.